Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Abbvie 4Q Results | Contract Pharma

What are you searching for?

Sign in

Abbvie 4Q Results

Immunology portfolio sales were $7.9 billion, up 18% driven by Skyrizi; hematologic oncology portfolio sales were $1.6 billion, down 13%.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Abbvie
4Q Revenues: $15.1 billion (+2%)
4Q Earnings: $2.5 billion (-39%)
FY Revenues: $58.1 billion (+3%)
FY Earnings: $11.8 billion (+3%)
Comments: Global revenues from the immunology portfolio were $7.9 billion in the quarter, up 18%. Humira sales were $5.6 billion, up 5%. U.S. Humira sales were $5.0 billion, an increase of 10% percent, while international sales were $573 million, down 27% due to biosimilar competition. Skyrizi sales were $1.6 billion, up 76%. Rinvoq sales were $770 million, up 49%.
 
Global revenues from the hematologic oncology portfolio were $1.6 billion in the quarter, down 13%. Imbruvica sales were $1.1 billion, down 20%, with U.S. sales of $841 million and international profit sharing of $274 million. Venclexta sales were $516 million, up 6%.
 
Global revenues from the neuroscience portfolio were $1.7 billion, an increase of 3%. Botox Therapeutic sales were $728 million, up 9%. Vraylar sales were $565 million, an increase of 16%. Ubrelvy sales were $197 million, up 8%.
 
Global revenues from the aesthetics portfolio were $1.3 billion, down 9%. Botox Cosmetic sales were $642 million, up 3%. Juvederm sales were $322 million, down 25%.  

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters